Literature DB >> 20872237

Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8.

Yoshihiro Yui1, Kazuyuki Itoh, Kiyoko Yoshioka, Norifumi Naka, Motonobu Watanabe, Yoshimi Hiraumi, Hiroshi Matsubara, Ken-ichiro Watanabe, Kazumi Sano, Tatsutoshi Nakahata, Souichi Adachi.   

Abstract

The outcomes of osteosarcoma patients still remain poor because of intractable pulmonary metastasis. We previously established a highly metastatic osteosarcoma cell line, LM8 from Dunn mouse osteosarcoma by in vivo selection. We herein aimed to clarify the characteristic biological features related with high metastatic potential and new target molecules to suppress pulmonary metastasis of osteosarcoma, using this syngeneic spontaneous metastatic model. LM8 cells acquired fibroblastic morphology with striking filopodia on the cell surface. Immunostaining showed faint stress fiber formation and peripherally localized integrin β1, and biochemical analyses showed the activated Cdc42 and autophosphorylation of focal adhesion kinase (FAK) in LM8 cells when compared to Dunn cells. LM8 cells had activated motility in single cell migration mode. LM8 migration was increased by a Rho-associated kinase (ROCK) inhibitor, Y-27632, while decreased by Cdc42 silencing using RNA interference system. We found that a clinically approved camptothecin analog, irinotecan suppressed the migration, Cdc42 activity, and autophosphorylation of FAK, and attenuated integrin β1 distribution selectively in LM8 cells. Daily oral administration of irinotecan significantly reduced the rate and size of pulmonary metastasis in syngeneic C3H mice. The fibroblastic morphology and activated cell migration with the dependency on Cdc42 but not Rho-ROCK signaling pathway argued that LM8 moved in mesenchymal mode of cell migration. This activated mesenchymal migration was a key component of the pulmonary metastasis of LM8 cells. The inhibition of mesenchymal migration by irinotecan, in addition to its cytotoxic effects, might be effective in preventing pulmonary metastasis of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872237     DOI: 10.1007/s10585-010-9352-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  39 in total

1.  HISTOLOGY OF SOME NEOPLASMS AND NON-NEOPLASTIC LESIONS FOUND IN WILD MICE MAINTAINED UNDER LABORATORY CONDITIONS.

Authors:  T B DUNN; H B ANDERVONT
Journal:  J Natl Cancer Inst       Date:  1963-10       Impact factor: 13.506

Review 2.  Cell migration in tumors.

Authors:  Hideki Yamaguchi; Jeffrey Wyckoff; John Condeelis
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

3.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

Review 4.  Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery.

Authors:  Yves Pommier; Jacqueline Cherfils
Journal:  Trends Pharmacol Sci       Date:  2005-03       Impact factor: 14.819

Review 5.  The pathogenesis of cancer metastasis.

Authors:  G Poste; I J Fidler
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

6.  Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

Authors:  Allen M Goorin; Douglas J Schwartzentruber; Meenakshi Devidas; Mark C Gebhardt; Alberto G Ayala; Michael B Harris; Lee J Helman; Holcombe E Grier; Michael P Link
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

Review 7.  Rho GTPases in cancer cell biology.

Authors:  Francisco M Vega; Anne J Ridley
Journal:  FEBS Lett       Date:  2008-05-05       Impact factor: 4.124

8.  Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton.

Authors:  X D Ren; W B Kiosses; M A Schwartz
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

9.  Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo.

Authors:  Takeshi Kashima; Kazuya Nakamura; Jitsutaro Kawaguchi; Masakatsu Takanashi; Tsuyoshi Ishida; Hiroyuki Aburatani; Akira Kudo; Masashi Fukayama; Agamemnon E Grigoriadis
Journal:  Int J Cancer       Date:  2003-03-20       Impact factor: 7.396

10.  Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

Authors:  Ian J Lewis; Marianne A Nooij; Jeremy Whelan; Matthew R Sydes; Robert Grimer; Pancras C W Hogendoorn; Muhammad A Memon; Simon Weeden; Barbara M Uscinska; Martine van Glabbeke; Anne Kirkpatrick; Esther I Hauben; Alan W Craft; Antonie H M Taminiau
Journal:  J Natl Cancer Inst       Date:  2007-01-17       Impact factor: 13.506

View more
  13 in total

Review 1.  Small Rho GTPases in the control of cell shape and mobility.

Authors:  Arun Murali; Krishnaraj Rajalingam
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

2.  Protein phosphatase 2A Cα regulates proliferation, migration, and metastasis of osteosarcoma cells.

Authors:  Di Yang; Hirohiko Okamura; Hiroyuki Morimoto; Jumpei Teramachi; Tatsuji Haneji
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

3.  Mesenchymal-mode migration assay and antimetastatic drug screening with high-throughput microfluidic channel networks.

Authors:  Yuanqing Zhang; Weijia Zhang; Lidong Qin
Journal:  Angew Chem Int Ed Engl       Date:  2014-01-29       Impact factor: 15.336

4.  Lichen Secondary Metabolite, Physciosporin, Inhibits Lung Cancer Cell Motility.

Authors:  Yi Yang; So-Yeon Park; Thanh Thi Nguyen; Young Hyun Yu; Tru Van Nguyen; Eun Gene Sun; Jayalal Udeni; Min-Hye Jeong; Iris Pereira; Cheol Moon; Hyung-Ho Ha; Kyung Keun Kim; Jae-Seoun Hur; Hangun Kim
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

5.  Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas.

Authors:  Philip Wong; Angela Hui; Jie Su; Shijun Yue; Benjamin Haibe-Kains; Nalan Gokgoz; Wei Xu; Jeff Bruce; Justin Williams; Charles Catton; Jay S Wunder; Irene L Andrulis; Rebecca Gladdy; Brendan Dickson; Brian O'Sullivan; Fei-Fei Liu
Journal:  Oncotarget       Date:  2015-11-17

6.  Inhibitory Activity of (+)-Usnic Acid against Non-Small Cell Lung Cancer Cell Motility.

Authors:  Yi Yang; Thanh Thi Nguyen; Min-Hye Jeong; Florin Crişan; Young Hyun Yu; Hyung-Ho Ha; Kyung Hee Choi; Hye Gwang Jeong; Tae Cheon Jeong; Kwang Youl Lee; Kyung Keun Kim; Jae-Seoun Hur; Hangun Kim
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

7.  Sodium butyrate induces senescence and inhibits the invasiveness of glioblastoma cells.

Authors:  Hidemitsu Nakagawa; Satoru Sasagawa; Kazuyuki Itoh
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

8.  Identification of a p53 target, CD137L, that mediates growth suppression and immune response of osteosarcoma cells.

Authors:  Yusuke Tsuda; Chizu Tanikawa; Takafumi Miyamoto; Makoto Hirata; Varalee Yodsurang; Yao-Zhong Zhang; Seiya Imoto; Rui Yamaguchi; Satoru Miyano; Hiroshi Takayanagi; Hirotaka Kawano; Hidewaki Nakagawa; Sakae Tanaka; Koichi Matsuda
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

9.  Hybrid liposomes inhibit tumor growth and lung metastasis of murine osteosarcoma cells.

Authors:  Hideki Kitajima; Yuji Komizu; Hideaki Ichihara; Koichi Goto; Ryuichi Ueoka
Journal:  Cancer Med       Date:  2013-03-22       Impact factor: 4.452

10.  Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy.

Authors:  Takaaki Tanaka; Yoshihiro Yui; Norifumi Naka; Toru Wakamatsu; Kiyoko Yoshioka; Nobuhito Araki; Hideki Yoshikawa; Kazuyuki Itoh
Journal:  Clin Exp Metastasis       Date:  2012-10-18       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.